Back to Search Start Over

Late-onset opportunistic infections while receiving anti-retroviral therapy in Latin America: burden and risk factors.

Authors :
Núñez I
Crabtree-Ramirez B
Shepherd BE
Sterling TR
Cahn P
Veloso VG
Cortes CP
Padgett D
Gotuzzo E
Sierra-Madero J
McGowan CC
Person AK
Caro-Vega Y
Source :
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2022 Sep; Vol. 122, pp. 469-475. Date of Electronic Publication: 2022 Jun 26.
Publication Year :
2022

Abstract

Objectives: The aim of this study was to describe the incidence, clinical characteristics, and risk factors of late-onset opportunistic infections (LOI) in people who live with HIV (PWLHA) within the Caribbean, Central and South America network for HIV epidemiology.<br />Methods: We performed a retrospective cohort study including treatment-naive PWLHA enrolled at seven sites (Argentina, Brazil, Chile, Peru, Mexico, and two sites in Honduras). Follow-up began at 6 months after treatment started. Outcomes were LOI, loss to follow-up, and death. We used a Cox proportional hazards model and a competing risks model to evaluate risk factors.<br />Results: A total of 10,583 patients were included. Median follow up was at 5.4 years. LOI occurred in 895 (8.4%) patients. Median time to opportunistic infection was 2.1 years. The most common infections were tuberculosis (39%), esophageal candidiasis (10%), and Pneumocystis jirovecii (P. jirovecii) pneumonia (10%). Death occurred in 576 (5.4%) patients, and 3021 (28.5%) patients were lost to follow-up. A protease inhibitor-based regimen (hazard ratio 1.25), AIDS-defining events during the first 6 months of antiretroviral-treatment (hazard ratio 2.12), starting antiretroviral-treatment in earlier years (hazard ratio 1.52 for 2005 vs 2010), and treatment switch (hazard ratio 1.31) were associated with a higher risk of LOI.<br />Conclusion: LOI occurred in nearly one in 10 patients. People with risk factors could benefit from closer follow-up.<br /> (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Details

Language :
English
ISSN :
1878-3511
Volume :
122
Database :
MEDLINE
Journal :
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Publication Type :
Academic Journal
Accession number :
35768025
Full Text :
https://doi.org/10.1016/j.ijid.2022.06.041